Medical Condition News

RSS

Red and processed meat ‘ups’ risk for type 2 diabetes

A new study conducted by researchers at the Harvard School of Public Health says that a diet heavy on red meat and processed foods can significantly increase a person’s chances of developing type 2 diabetes. The study results were published in the American Journal of Clinical Nutrition.

11 Aug 2011

Viewpoints: High-cost drugs and Medicare; pitfalls for ACOs; federal funding fix for nursing homes

Life-extending drugs debut frequently, and they usually seem exorbitantly expensive when weighed against their promise of adding a few weeks or months of life to someone with a terminal illness. In these prostate-cancer cases, one new drug costs $5,000 a month, another $8,000 every three weeks and a third $93,000 for a full course of treatment.

11 Aug 2011

Music therapy for cancer: Relieves anxiety and pain

According to a new analysis of previously published research singing, playing an instrument or even just listening to music may lessen anxiety in cancer patients and improve their overall quality of life.

11 Aug 2011

57 genes associated with multiple sclerosis

An international research team has found nearly 30 genetic risk factors that predispose to developing multiple sclerosis. It brings to more than 50 the total number of genetic clues to the disease. The research, published in Nature, will help identify risk factors and perhaps future treatments or even a cure, hopes the MS Society.

11 Aug 2011

Modified spider-silk proteins for nonviral gene delivery

Genetically engineered spider silk could help overcome a major barrier to the use of gene therapy in everyday medicine, according to a new study that reported development and successful initial laboratory tests of such a material. It appears in ACS' journal Bioconjugate Chemistry.

11 Aug 2011

Gene therapy to combat leukemia

In a medical breakthrough scientists have found that gene therapy could be used to cure leukemia. Researchers at the University of Pennsylvania engineered patients' own pathogen-fighting T-cells to target a molecule found on the surface of leukemia cells. These genetically modified T-cells were grown outside of the body and infused back into patients suffering from late-stage chronic lymphocytic leukemia (CLL), which affects the blood and bone marrow and is the most common form of leukemia.

11 Aug 2011

Gastroenterology journal publishes results of Lexicon LX1031 Phase 2 trial in IBS

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced today that results from the Phase 2 clinical trial of LX1031 in patients with non-constipating irritable bowel syndrome (IBS) were published earlier this week in the August 2011 edition of the journal Gastroenterology.

11 Aug 2011

Neoprobe seeks FDA marketing approval of Lymphoseek for use in ILM oncology procedure

Neoprobe Corporation, a diversified developer of innovative oncology surgical and diagnostic products, today announced it has submitted a New Drug Application (NDA) for Lymphoseek to the U.S. Food and Drug Administration.

11 Aug 2011

Positive results from two ADL5945 Phase 2 studies for opioid-induced constipation

Adolor Corporation today announced positive, statistically significant top line results from its two Phase 2 studies of ADL5945 in chronic non-cancer pain patients with opioid-induced constipation.

11 Aug 2011

Mercury and autism link strengthened

The researchers from Swinburne University in Melbourne surveyed 522 Australian survivors of Pink disease - a form of mercury poisoning common in the early 20th century - found one in 25 of their 398 grandchildren aged six to 12 had an autism spectrum disorder.

10 Aug 2011

FDA acceptance of peginesatide NDA triggers $10M milestone payment to Affymax

Affymax, Inc. today announced that it has received a $10 million development milestone payment from Takeda Pharmaceutical Company as part of the companies' exclusive global agreement to develop and commercialize peginesatide (formerly known as Hematide™), Affymax's investigational drug for the treatment of anemia in chronic renal failure patients.

10 Aug 2011

FDA approves Abbott's RX Herculink Elite Renal Stent System for renal artery stenosis

Abbott today announced it has received U.S. Food and Drug Administration (FDA) approval for the RX Herculink Elite® Renal Stent System for the treatment of renal artery stenosis (narrowing of the main arteries supplying blood to the kidneys) in patients with uncontrolled hypertension (high blood pressure).

10 Aug 2011

Patients receive inadequate medical monitoring for prescribed drugs in psychiatric settings

New research from the University of Leicester demonstrates that psychiatrists are not offering adequate checks for metabolic complications that are common in patients with mental ill health - especially those prescribed antipsychotic medication.

10 Aug 2011

NCI, Genesis Biopharma sign CRADA agreement to develop cancer immunotherapies

Genesis Biopharma, Inc., a biotechnology company developing targeted cancer immunotherapies, today announced it has signed a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute.

10 Aug 2011

People more likely to use bowel screen test kit with GP letter

A letter of endorsement from their local doctor as well as a 'how-to-do-it' leaflet makes more people take part in bowel screening home tests - says a new study published in the British Journal of Cancer, today.

10 Aug 2011

China Medical receives SFDA approvals for TOP2A and prostate cancer FISH detection kits

China Medical Technologies, Inc., a leading China-based advanced in-vitro diagnostic company, today announced that it has received approvals for its prostate cancer FISH detection kit and Topoisomerase 2-alpha FISH detection kit from the State Food and Drug Administration of the People's Republic of China.

10 Aug 2011

Israeli OCS approves $1.7M grant to support PROLOR's hGH-CTP program

PROLOR Biotech, Inc., a company developing next generation biobetter therapeutic proteins, today announced that the Israeli Office of the Chief Scientist (OCS) has approved a 2011 grant to PROLOR's Israeli-based R&D subsidiary for the company's development program for hGH-CTP, its long-acting version of human growth hormone.

10 Aug 2011

Cancer-causing fusion protein works by silencing tumor suppressor gene IL-2Rγ

Mariusz A. Wasik, MD, professor of Pathology and Laboratory Medicine, and Qian Zhang, MD, PhD, research assistant professor, both from the Perelman School of Medicine at the University of Pennsylvania, and their colleagues, found that a cancer-causing fusion protein works by silencing the tumor suppressor gene IL-2R common gamma-chain.

10 Aug 2011

Study suggests ways to remediate cognitive errors

Concern about the capacity of individuals with schizophrenia to consent to clinical research studies has largely focused on impairment due to psychotic symptoms associated with the disorder. Less attention has been given to the cognitive errors that prospective participants make when undergoing a formal assessment of decisional capacity.

10 Aug 2011

TrovaGene regains ownership of worldwide rights to transrenal technology

TrovaGene, Inc., a developer of transrenal molecular diagnostics, confirmed today that it regained ownership of its worldwide rights and control over its patent estate for transrenal technology for non-invasive prenatal applications and cancer through the termination of a license agreement between TrovaGene and Sequenom, Inc.

10 Aug 2011